IP Library Patent Application 15074716
Patent Application
App. No. 15/074,716

METHODS OF THERAPEUTIC MONITORING OF NITROGEN SCAVENGING DRUGS

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
15/074,716
Abstract

The present disclosure provides methods for evaluating daily ammonia exposure based on a single fasting ammonia blood level measurement, as well as methods that utilize this technique to adjust the dosage of a nitrogen scavenging drug, determine whether to administer a nitrogen scavenging drug, and treat nitrogen retention disorders.

Claims (16)

1 .- 11 . (canceled)

12 . A method of treating a subject with a urea cycle disorder who has previously been administered an initial dosage of glyceryl tri-[4-phenylbutyrate], and who has a fasting plasma ammonia level less than the upper limit of normal for plasma ammonia level, the method comprising:

(a) measuring a fasting plasma ammonia level for the subject by analyzing, a plasma sample from the subject that has been stored at 0-15° C.;

(b) comparing the fasting plasma ammonia level to the upper limit of normal for plasma ammonia level; and

(c) if the fasting plasma ammonia level is greater than half the upper limit of normal for plasma ammonia level, administering an increased dosage of glyceryl tri-[4-phenylbutyrate].

13 . The method of claim 12 , wherein the plasma sample is analyzed within 3 hours of collection.

14 . The method of claim 12 , wherein the plasma sample is analyzed within less than 1 hour of collection.

15 . The method of claim 12 , wherein the plasma sample is analyzed immediately after collection.

16 . The method of claim 12 , further comprising repeating steps (a) to (c) until the subject exhibits a fasting plasma ammonia level at or below half the upper limit of normal for plasma ammonia level.

17 . The method of claim 12 , wherein the upper limit of normal for plasma ammonia level is 35 μmol/L.

18 . The method of claim 12 , wherein the adjusted dosage of glyceryl tri-[4-phenylbutyrate] is administered orally.

19 . A method of treating a subject with a urea cycle disorder who has previously been administered an initial dosage of glyceryl tri-[4-phenylbutyrate], and who has a fasting plasma ammonia level less than the upper limit of normal for plasma ammonia level, the method comprising:

(a) measuring a fasting plasma ammonia level for the subject by analyzing a plasma sample from the subject that has been stored at below 0° C.;

(b) comparing the fasting plasma ammonia level to the upper limit of normal for plasma ammonia level; and

(c) if the fasting plasma ammonia level is greater than half the upper limit of normal for plasma ammonia level, administering an increased dosage of glyceryl tri-[4-phenylbutyrate].

20 . The method of claim 19 , wherein the plasma sample is stored at ≦−18° C.

Assignments (5)
CORRECTIVE ASSIGNMENT TO CORRECT THE TWO PATENT NUMBERS PREVIOUSLY RECORDED AT REEL: 039640 FRAME: 0886. ASSIGNOR(S) HEREBY CONFIRMS THE CHANGE OF NAME. Recorded Apr 17, 2017
From: HORIZON THERAPEUTICS INC.
To: HORIZON THERAPEUTICS, LLC
Reel/Frame 043156/0175 →
CHANGE OF NAME Recorded Aug 26, 2016
From: HORIZON THERAPEUTICS, INC.
To: HORIZON THERAPEUTICS, LLC
Reel/Frame 039640/0886 →
CHANGE OF NAME Recorded Aug 9, 2016
From: HORIZON THERAPEUITCS, INC.
To: HORIZON THERAPEUTICS, LLC
Reel/Frame 039633/0851 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 20, 2016
From: SCHARSCHMIDT, BRUCE
To: HORIZON THERAPEUTICS, INC.
Reel/Frame 038960/0037 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 20, 2016
From: MOKHTARANI, MASOUD
To: HORIZON THERAPEUTICS, INC.
Reel/Frame 038960/0089 →